Travere Therapeutics (NASDAQ:TVTX) Insider Sells $900,000.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 20,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $45.00, for a total transaction of $900,000.00. Following the transaction, the insider directly owned 111,473 shares of the company’s stock, valued at approximately $5,016,285. This represents a 15.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Wednesday, May 6th, Jula Inrig sold 311 shares of Travere Therapeutics stock. The shares were sold at an average price of $43.95, for a total transaction of $13,668.45.
• On Tuesday, May 5th, Jula Inrig sold 2,174 shares of Travere Therapeutics stock. The shares were sold at an average price of $46.65, for a total transaction of $101,417.10.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The shares were sold at an average price of $42.61, for a total transaction of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The shares were sold at an average price of $41.93, for a total transaction of $302,524.95.

Travere Therapeutics Trading Down 0.1%

NASDAQ TVTX opened at $42.60 on Friday. Travere Therapeutics, Inc. has a 12 month low of $13.88 and a 12 month high of $48.61. The company has a 50-day moving average of $32.83 and a 200-day moving average of $32.94. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. The company has a market cap of $3.96 billion, a P/E ratio of -185.21 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The firm had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The company’s revenue was up 55.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.47) EPS. As a group, equities analysts predict that Travere Therapeutics, Inc. will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Citigroup increased their target price on shares of Travere Therapeutics from $53.00 to $59.00 and gave the stock a “buy” rating in a research report on Tuesday. Guggenheim increased their target price on shares of Travere Therapeutics from $54.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. Weiss Ratings downgraded shares of Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Wedbush increased their target price on shares of Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, HC Wainwright upped their price target on Travere Therapeutics from $47.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $47.83.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Hedge Funds Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming purchased a new position in shares of Travere Therapeutics during the 4th quarter valued at approximately $37,000. Torren Management LLC purchased a new position in shares of Travere Therapeutics during the 4th quarter valued at approximately $38,000. Comerica Bank boosted its stake in shares of Travere Therapeutics by 77.5% during the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after buying an additional 492 shares during the last quarter. Fifth Third Bancorp purchased a new position in shares of Travere Therapeutics during the 1st quarter valued at approximately $35,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Travere Therapeutics by 69.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after buying an additional 487 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.